Key facts
- InterShunt’s last known valuation is $140.0M.
- It has raised $31.4M; the latest was Later Stage VC ($23.4M) in Sep 2024.
- Notable investors include MedTech Innovator, gBETA, IAG Capital Partners, BioGenerator Ventures, Accelerate Venture Partners — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for InterShunt
- ·The full record, as it builds
Funding rounds
No funding rounds for InterShunt are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About InterShunt
Developer of a proprietary catheter system designed to provide relief to people suffering from heart failure. The company's system is an interatrial shunting device that requires no implant and no energy for the capturing and excision of tissue from the interatrial septum, enabling doctors to reduce left atrial pressure in heart failure patients.
- Sector
- Healthcare
- HQ
- Plymouth, MN, United States
- Founded
- 2015
- Employees
- 10
- Website
- intershunt.com/
- Ownership
- Privately Held (backing)
InterShunt doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in InterShunt shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on InterShunt in its N-PORT filings yet. We sweep new filings monthly.